PEGylated lactoferrin enhances its hepatoprotective effects on acute liver injury induced by D-galactosamine and lipopolysaccharide in rats.
Polyethylene glycol (PEG) is attached to proteins in order to increase their half-life in circulation and reduce their immunogenicity in vivo. The present study was conducted to examine whether two different sizes of PEGylated bovine lactoferrin (40k- and 20k-PEG-bLf) would enhance the protective effect of native bLf on liver injury induced by D-galactosamine (GalN) and lipopolysaccharide (LPS) in rats. The treatment of PEGylated bLf more remarkably prevented the elevation of serum levels of hepatic enzyme markers and inhibited inflammatory and hemorrhagic changes and hepatic apoptosis induced by GalN/LPS than native bLf. The treatment of PEGylated bLf more significantly inhibited the increased concentration of proinflammatory cytokines (TNF-alpha and IL-6) in serum caused by GaIN/LPS, and enhanced anti-inflammatory cytokine (IL-10) production more than native bLf. PEGylated bLf decreased serum levels of nitric oxide (NO) more than native bLf. These results indicate that PEGylated bLf inhibits more significantly the induction of inflammatory mediators such as cytokines and NO than native bLf, resulting in the enhancement of its prevention of fulminant liver failure induced by GalN/LPS in rats. The present study provided evidence that PEGylated bLf may offer a novel alternative therapy for the prevention of acute hepatic failure through its anti-inflammatory and immunomodulatory properties.
Sugiyama
Akihiko
A
Course of Veterinary Laboratory Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4-101 Minami, Koyama-cho, Tottori, Tottori 680-8553, Japan. sugiyama@muses.tottori-u.ac.jp
Sato
Atsushi
A
Shimizu
Hirohiko
H
Ando
Kunio
K
Takeuchi
Takashi
T
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D016207:Cytokines / Q000097:blood; D004195:Disease Models, Animal; D005688:Galactosamine / Q000378:metabolism; D006651:Histocytochemistry; D007781:Lactoferrin / Q000008:administration & dosage / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000378:metabolism; D017114:Liver Failure, Acute / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control; D008297:Male; D009569:Nitric Oxide / Q000097:blood; D010865:Pilot Projects; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D016207:Cytokines; D008070:Lipopolysaccharides; D009569:Nitric Oxide; D011092:Polyethylene Glycols; D005688:Galactosamine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D007781:Lactoferrin